Edition:
United States

Profile: Vical Inc (VICL.OQ)

VICL.OQ on NASDAQ Stock Exchange Capital Market

2.41USD
22 Sep 2017
Change (% chg)

$0.00 (+0.00%)
Prev Close
$2.41
Open
$2.40
Day's High
$2.40
Day's Low
$2.40
Volume
30
Avg. Vol
8,215
52-wk High
$3.26
52-wk Low
$2.06

Vical Incorporated researches and develops biopharmaceutical products based on its deoxyribonucleic acid (DNA) delivery technologies for the prevention and treatment of life-threatening diseases. The Company has approximately four active, independent, or partnered development programs in the areas of infectious disease including Phase III clinical trial of ASP0113 for prevention of cytomegalovirus (CMV) reactivation in stem cell transplant recipients and Phase II clinical trial of ASP0113 for prevention of CMV infection in kidney transplant recipients; Phase I/II clinical trial of its therapeutic genital herpes vaccine, designed to reduce viral shedding and genital herpes lesions in herpes simplex virus type 2 (HSV-2) infected patients; an ongoing Phase I program of VL-2397 for invasive fungal infections, and completed preclinical program, with an allowed investigational new drug application (IND) using its CyMVectin prophylactic vaccine formulated with its Vaxfectin adjuvant.

Company Address

Vical Inc

10390 Pacific Center Ct
SAN DIEGO   CA   92121-4340
P: +1858.6461100
F: +1302.6555049

Company Web Links